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Abstract
Background: Maspin, a member of the serpin family, is a suppressor of tumor growth, an inhibitor
of angiogenesis and an inducer of apoptosis. Maspin induces apoptosis by increasing Bax, a member
of the Bcl-2 family of apoptosis-regulating proteins. In this exploratory study, we investigated the
associated expression of Maspin and Bax proteins as a potential prognostic factor in intrahepatic
cholangiocarcinoma (IHCCA).
Methods:  Twenty-two paraffin-embedded samples were analyzed by immunohistochemical
methods using Maspin, Bax and CD34 antibodies. Maspin was scored semiquantitatively
(HSCORE). Apoptosis was assessed using an antibody against cleaved caspase-3.
Results: The strong relationship observed between the expression of Maspin and Bax, indicates
that Bax is likely to be the key effector of Maspin-mediated induction of apoptosis as indicated by
the activation of cleaved caspase-3. We categorized Maspin HSCORE by calculating the optimal
cutpoint. A Maspin HSCORE above the cutpoint was inversely related with tumor dimension,
depth of tumor and vascular invasion. Uni/multivariate analysis suggests that a Maspin HSCORE
below the cutpoint significantly worsens the patients' prognosis. Tumors with Maspin HSCORE
below the cutpoint had a shorter survival (11+/-5 months) than did patients with Maspin HSCORE
above the cutpoint (27+/-4 months), whereas Kaplan-Meier analysis and logrank test showed no
significant difference in overall survival between the patients.
Conclusion: The associated expression of Maspin and Bax might delay tumor progression in
IHCCA. Maspin above the cutpoint might counteract tumor development by increasing cell
apoptosis, and by decreasing tumor mass and cell invasion. The combined expression of Maspin and
Bax appears to influence the susceptibility of tumor cholangiocytes to apoptosis and thus may be
involved in delaying IHCCA progression.
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Background
Cholangiocarcinoma is a rare tumor that is difficult to
diagnose and is associated with a high mortality [1-3]. The
term cholangiocarcinoma referred originally to just pri-
mary tumors of the intrahepatic bile ducts, while now it is
regarded as inclusive of intrahepatic, perihilar, and distal
extrahepatic tumours of the bile ducts [4]. The incidence
of intrahepatic bile duct carcinoma (IHCCA) is increasing
worldwide, although the cause for this rise is unclear
[1,2]. It could be related to an interplay between predis-
posing genetic factors and environmental triggers. Surgi-
cal resection is the only curative option for
cholangiocarcinoma, particularly for extrahepatic ones,
with results depending on technique and patient selection
[5-9]. Chemotherapy and radiotherapy are ineffective in
patients with inoperable tumors. and biliary drainage is
the mainstay of palliation [10,11]. Over the last ten years,
considerable effort has been devoted to the search for
markers to improve the diagnosis and the management of
CCA. One of the authors (AAR) has developed a Perl [12]
script for differential in silico screening between cancer
and normal EST tissue libraries devoted to the identifica-
tion of differentially expressed genes. Expressed Sequence
Tag (EST) sequencing [13] is of value in discovering new
genes (or rather markers), and provides an inexpensive
approach to identifying large numbers of new genes
[14,15]. These can be used in gene differential expression
screening procedures. The widely recognized contribution
of ESTs to gene discovery has spurred the production of
very large numbers of these sequences. There are currently
over 6.0 × 106 human EST sequences in the public data-
bases [16] and ESTs represent more than 60% of the Gene
Bank database entries. Using this procedure, a pool of
mRNA sequences were identified that, on a statistical basis
[17,18], are preferentially expressed in hepatocarcinoma
and cholangiocarcinoma (data not shown). We focused
our attention on those over-expressed genes known to
counteract or delay tumor progression. Among these
genes, we selected the Maspin gene whose protein product
belongs to the family of protease inhibitors, and has been
described as an apoptosis-sensitizing protein [19].
Maspin (mammary serine protease inhibitor) is a member
of the serpin (serine protease inhibitor) family [20,21] and
has recently been described as a clinically relevant factor
in several types of tumor [22-25]. A decreased expression
of Maspin has been related to the progression of breast
cancer, and the loss of its expression is regarded as a criti-
cal step during the transition from non-invasive to inva-
sive breast cancer [26,27]. It has been suggested that
Maspin could be a reliable predictor for metastatic disease
[28] and a clinical relevant inhibitor of tumor progression
[29].
The mechanism of Maspin action is still controversial and
it could act as an inhibitor of angiogenesis[30,31], and
suppressor of tumor growth and metastasis in vivo
[32,33]. There is increasing evidence that in addition to its
anti-angiogenic effect, Maspin can induce apoptosis of
tumor cells. Moreover, Maspin over-expression modulates
tumor cell apoptosis through the regulation of Bcl-2 fam-
ily proteins [34] resulting in an increased release of cyto-
chrome C from mitochondria [35] and an increased
apoptosis in Maspin-expressing cells [36]. Other work
showed that in Maspin- expressing cells, the Bcl-2 level
was decreased and the level of pro-apoptotic protein Bax
was significantly increased In a recent study [19], the
authors obtained cellular, molecular, and biochemical
evidence that supports a key role for Bax in sensitization
of Maspin-mediated apoptosis. Thus, Bax over-expression
may predict an elevated cellular apoptotic response to a
broad spectrum of apoptotic stimuli.
To our knowledge, the combined role of Maspin and Bax
in IHCCA has been not investigated. The aim of this
exploratory study was to assess the associated expression
patterns of Maspin and Bax in specimens of IHCCA and to
investigate whether Maspin and Bax might be used as
novel prognostic factors.
Methods
Patient selection
From January 1997 to December 2005, 33 patients
affected by cholangiocarcinoma were admitted to the Sur-
gery department. Five patients did not undergo surgery
because of advanced disease, advanced liver cirrhosis or
poor general condition. The remaining 28 patients (9
males and 19 females) with an average age of 68 years
(range: 36–79), underwent liver resection for cholangi-
ocarcinoma at the Dipartimento di Scienze Chirurgiche,
Sezione di Clinica Chirurgica Generale e dei Trapianti
d'Organo. Of these 28 patients, 22 had IHCCA and six
patients had hilar extrahepatic cholangiocarcinoma (Klat-
skin): 3 patients of type IIIb, 2 had a peripheral type and
one had a periductal type according to the Bismuth-Cor-
lette indication.
We focused our attention on IHCCA, since the epidemio-
logical data, retrieved from the Parma Tumor Registry
(Divisione di Oncologia Medica, Azienda Ospedaliera di
Parma), showed a marked increase in IHCCA in our prov-
ince from 1–2 cases/year in 1994 to 9–12 cases/year in
2002–2004.
Background information including clinico-pathologic
data, and patients' survival was retrieved from histologic
and clinical records. None of the patients had received
chemotherapy or radiotherapy prior to surgery. All surgi-
cal procedures were performed with radical intent (R0BMC Cancer 2006, 6:255 http://www.biomedcentral.com/1471-2407/6/255
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after surgery). Liver needle biopsies of five patients
included in this study were available.
The study was conducted in accordance with the tenets of
the Declaration of Helsinki. Following the indication of
Italian DLgs no. 196/03 (Codex on Privacy), every precau-
tion has been taken to respect the privacy of the patients
and the confidentiality of the patient's information. Writ-
ten consent to use stored tissue was obtained from all the
living patients.
Sample sources
The samples were retrieved from the archived files of the
Dipartimento di Patologia e Medicina di Laboratorio –
Sezione di Anatomia ed Istologia Patologica. Formalin-
fixed, paraffin-embedded, hematoxylin-eosin-stained sec-
tions were reviewed and the pathologist (PC) re-staged
the samples according to the recent AJCC classification
[37]. Sections with poorly differentiated tumor areas with
adjacent normal and/or dysplastic tissues were then
selected for immunohistochemical studies.
Immunohistochemistry
The paraffin sections were dewaxed, rehydrated, washed
in Tris-buffered saline (TBS) (150 mmol/L NaCl, 50
mmol/L Tris, pH 7.4). The antigen determinants masked
by formalin-fixation and paraffin-embedding were
exposed by heating the section in a microwave oven for 10
min in an epitope retrieval solution (10 mM Tris Base, 1 mM
EDTA solution, 0.05% (v/v) Tween 20, pH 9.0). The sec-
tions used for the pan-endothelial-cell marker CD34 were
treated with 1 mg/ml protease type XXIV [38] (Sigma-
Aldrich, Inc., St. Louis, MO). The endogenous peroxidase
activity was quenched with 3% H2O2 in deionized water
for 10 min. Non-specific bindings were blocked in TBS
containing 5% acetylated albumin (Aurion, Wegeningen,
The Netherlands), 5% normal mouse serum (Dako Corp.,
Carpinteria, CA) and 0.1% porcine gelatin type B (Sigma-
Aldrich). The primary antibodies against Maspin (Novo-
castra, Newcastle upon Tyne, UK), Bax and CD34 (Santa
Cruz Biotechnology, Inc. Santa Cruz, CA), and cleaved
caspase-3 (Cell Signaling Technology Inc., Beverly, MA)
were used at 1:35, 1:75, 1:50 and 1:200 dilutions, respec-
tively. Immunoperoxidase staining was performed using
an anti-Mouse/Rabbit Poly HRP Detection Kit (Chemicon
International, Temecula, CA) according to the manufac-
ture's specifications and developed with DAB. The speci-
mens were counterstained with hematoxylin, mounted
and examined by light microscopy. Routine negative con-
trols used TBS instead of the primary antibody. An isotype
control was conducted using a mouse IgG isotype control
serum (Dako Corp., Carpinteria, CA). Negative and iso-
type controls were used in all staining runs. All negative
and isotype controls resulted in negative immunohisto-
chemical reactions. Adjacent normal and/or dysplastic
areas were selected as internal controls. As positive con-
trols, sections from tumors known to express Maspin and/
or Bax were used (according to the manufacture's datash-
eet). A preparation of excised inflammatory tonsils was
used to asses cleaved caspase-3 expression.
The staining intensities of the IHCCAs and liver fine-nee-
dle biopsies were compared with those of adjacent non-
neoplastic biliary ducts and by semiquantitative visual
evaluation by three observers (PC, AAR and SD). Overex-
pression was considered to be present when the intensity
of tumor staining was at least twice the staining intensity
of adjacent non-neoplastic areas.
Image analysis
The expression of Maspin was evaluated using a micro-
scope image analysis system (Nikon Digital Net system).
For each patient, five randomized, non-overlapping rames
were evaluated in the same neoplastic area at 400× field
magnification (0.198 mm2·field). At least 50 cells were
counted for a total of 250–500 cells analyzed. Toassess
reproducibility of the image analysis, the pathologist (PC)
blindly scored the 66% of the total of patients and also
randomly selected frames.
Quantification of expression
Maspin and Bax immunopositivities were semi-quantita-
tively evaluated. This method described by McCarty [39]
is referred to as HSCORE. The percentage of positive cells
for Maspin or Bax, respectively, was linked with the inten-
sity of staining classified into four groups: 0-negative; 1-
slight positive (light brown color of the either homogene-
ously or spotty stained cells); 2-distinct positivity
(medium brown homogeneously stained cells); 3-strong
positivity (dark brown to black homogeneously stained
cells).
We calculated the HSCORE using this formula:
HSCORE = ∑Pi·(j+1),
where Pi is the percentage of positive cells in the sample
investigated, and j is one of the four positivity grades (0–
3) defined above.
Quantification of neoplastic cells expressing cleaved 
caspase-3
Cleaved caspase-3 positive neoplastic cells were quanti-
fied using a microscopic grid at 400× magnification and
expressed as percentages of all tumor cells present. More-
over, we carefully separated cleaved caspase-3 positive
lymphocytes and intratumoral macrophages from phago-
cytosed apoptotic debris. Apoptotic cells from highly
necrotic areas were excluded from the analysis.BMC Cancer 2006, 6:255 http://www.biomedcentral.com/1471-2407/6/255
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Evaluation of microvessel density
The procedure used was in accordance to the international
consensus method of intratumoral microvessel density
assessment [40] by using the pan-endothelial CD34
marker. The assessment was conducted according to our
recently published procedure [41]. For microvessel quan-
titation, the tumoral areas containing the highest number
of capillaries and small vessels were identified by light
microscopy at low power magnification. In each tumor,
three areas with the highest vascularization were identi-
fied, and a microvessel count was performed at x200 mag-
nification. Although agreement was not exact in every
case, no significant variation between the investigators'
counts (PC, AAR, SD) was noted.
Statistical analysis
The biomarker and clinical data were analyzed using S-
Plus Professional Edition v.6.1 (Insightful Corp., Seattle,
WA). Fisher's Exact Test was used to test the hypothesis of
independence between categorical variables in 2 × 2
tables. The ANOVA procedure was used to evaluate the
association between ordinal and categorical variables. All
tests were two-sided. The significance values higher than
0.05 and less than 0.10 indicated a trend. The conversion
of a continuous covariate into a binary one when there is
no established cut-off point (previous published results or
biological knowledge) was performed by using an out-
come-oriented statistical method (such as the optimal cut-
point estimation).
For optimal cutpoint estimation a corrected P value
method, as described by Hothorn and Lausen [42], was
used. Estimates of the survival probability were calculated
using the Kaplan-Meier method, and the logrank test was
employed to test the null hypothesis of equality in overall
survival among patients with Maspin above or below the
cutpoint. The hazard ratio associated with Maspin expres-
sion above or below the cutpoint was estimated by logistic
regression.
Results
Demographic data
This exploratory study concerned a relatively short period
of inclusion (7 years) for this tumor, with a satisfactory
homogeneity of patients treated with radical intent. T3he
average age of the 15 females and 7 males undergoing sur-
gery for IHCCA was 68 years (range 52–79). Two patients
out of 22 were positive to C viral hepatitis (one of them
showed B and C infection). None of the other patients
had chronic liver disease. At presentation, twelve patients
had one comorbidity (diabetes, hypertension or heart dis-
ease), eight patients had two comorbidities (mainly dia-
betes and hypertension), and only two patients had three
comorbidities (chronic obstructive lung disease, diabetes
and heart disease).
The surgical procedures, performed by one of the authors
(PS), for IHCCA included: 5 right trisectionectomies, 4
right and 3 left hemihepatectomies (including the
extended), 7 sectoriectomies (anterior, posterior and lat-
eral) and 3 segmentectomies. The mean liver volume
removed was 49 ± 19.2% (range 22–75%) while 4.5 ± 1.5
were the mean number of resected hepatic segments.
Seventeen (77%) out of 22 patients with IHCCA were
characterized as having well to moderate differentiation,
and 5 (23%) poor differentiation. The tumor growth pat-
tern was classified as papillary in five cases, glandular in
six, and solid in nine. Patient characteristics are summa-
rized in Table 1 according to Maspin HSCORE cutpoint.
Immunohistochemical detection of Maspin, Bax and 
cleaved Caspase-3
The immunohistochemical staining, performed with anti-
Maspin, anti-Bax monoclonal antibody and anti-cleaved-
caspase 3 polyclonal antibody respectively, produced
readily quantifiable results.
None of the samples exhibited Maspin expression in nor-
mal biliary tract epithelium (internal negative control). In
comparison, Maspin expression was present in 77% (17/
22) of IHCCA examined (see Figure 1A,C) and absent in
five patients (23%) In the sections analyzed, the number
of positive cells ranged from 0% to 61%, while the inten-
sity varied from negative specimens (grade 0) to dark
brown (grade 3). The Maspin-immunopositive cells basi-
cally showed three morphological staining patterns: (a)
cytoplasmatic (spotted or homogeneous), (b) nuclear,
and (c) both. The immunoreactivity for Maspin was com-
pletely negative in normal hepatocytes and in normal/dis-
plastic biliary duct far from IHCCA border and in all
hepatocarcinoma tested (data non shown). We note,
however, that in the analyzed IHCCA, the expression of
Maspin was present in those hepatocytes and/or displastic
biliary duct cells that surround the neoplastic areas. More-
over, in the Maspin-positive areas examined, the presence
of immunopositivity in the bile duct secretion, and a rein-
forcement of positivity along the luminal surface of tumor
bile ducts were sometimes observed.
The Maspin immunopositivities were semi-quantitatively
evaluated as described in the Methods section. Maspin
HSCORE ranged from 0 to 181.1 with a mean value of
71.3 ± 63.7 (median 69.7). The standardized skewness
and kurtosis values (0.723 and -1.426, respectively) are
within the range expected for data from a normal distribu-
tion.
Maspin is regarded as an apoptosis-sensitizing protein
[19]. The link between Maspin expression and apoptosis
induction has been explained by the regulation of pro-BMC Cancer 2006, 6:255 http://www.biomedcentral.com/1471-2407/6/255
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apoptotic Bcl-2 family proteins [34], resulting in predom-
inantly increased Bax expression.
Bax immunostaining was cytoplasmic and homogeneous.
We observed clear-cut expression of Bax in 45.5% (10/22)
of the evaluated specimens. In positive samples, it was
expressed in more than 75% of the neoplastic cells (see
Figure 1B,D). Interestingly, when Bax was expressed we
always observed Maspin expression (P- value = 0.039). Bax
HSCORE ranged from 0 to 248.1 with a mean value of
67.9 ± 96.5. Only the kurtosis value (0.036) was within
the range expected for data from a normal distribution.
The associated expression of Bax in Maspin positive sec-
tions might imply an activation of the apoptotic pathway.
Considering the central role of caspase-3 activation in
apoptosis, we then examined the occurrence of cleaved
caspase-3 in our Bax-positive IHCCA tissue samples. In 6
out 10 cases, cleaved caspase-3-positive neoplastic cells
were observed, albeit in a very limited number of cells.
The percentage of active caspase-3-positive tumor cells
ranged from 1 to 5%, displaying cytoplasmatic and/or
nuclear staining pattern (see Figure 2). The cytoplasmatic
staining showed two different patterns: spotted, granular
or homogeneous, while the intensity varied from light to
dark brown. The appearance of the active form of caspase-
3 in the cytoplasm of the neoplastic cells undergoing
apoptosis is an early event that precedes the development
of the classical morphological features of apoptosis.
In Bax-positive samples, cleaved caspase-3-positive infil-
trating lymphocytes were detected, serving as an internal
positive control. In some cases, granular cytoplasmic
staining in macrophages was also observed, probably rep-
resenting phagocytosed apoptotic debris.
Statistical correlation between Maspin HSCORE and 
clinical characteristics
Due to the small size of the cohort examined our study
should be viewed as exploratory. However, in the follow-
ing correlative analyses, the P values are reported as an
indication of confidence in the results, and will be used to
prioritize further testing. As shown in Figure 3, in the
absence of Bax the mean Maspin HSCORE value was of
36.6 ± 14 compared with 113.1 ± 16 when Bax was
present (P-value = 0.0035). It is noteworthy that there was
a linear relationship between Maspin and Bax HSCOREs
(P-value = 0.0425). We then decided to transform the con-
tinuous variable Maspin HSCORE into a categorical one
(binary variable) to make the model more interpretable.
By using the statistical procedure [42] described in the
Materials and Methods section, the lowest value of the
Table 1: Clinical-pathological features of patients affected by CCA who underwent surgery
Characteristic Patients with Maspin HSCORE 
above cutpoint (N = 13)
Patients with Maspin HSCORE 
below cutpoint (N = 9)
P-value
Age at surgery 69.3 + 7 67.3 + 10.3
Gender 0.647
Male 5 2
Female 8 7
Tumor greatest dimension 0.011
<4 cm 7 1
4–6 cm 5 2
>6 cm 1 6
Histologic grade 0.658
Well/Moderate 9 7
Poor 4 2
Percentage of tumor necrosis1# 0.550
<50 2 3
51–75 5 2
>75 6 4
Peritumoral border liver1# 0.103
Infiltrated 8 2
Pushed 5 6
Lymphoid infiltration1 0.342
Absent 7 3
Present 6 6
Stage 0.148
I4 0
II 2 1
III 7 8
1Estimated by pathologist (PC); #data on necrosis and peritumoral liver border status were not available for one patient.BMC Cancer 2006, 6:255 http://www.biomedcentral.com/1471-2407/6/255
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Maspin HSCORE that can discriminate the presence of
Bax was 39.12 (Figure 4, P-value = 0.00075). The Maspin
HSCORE was therefore categorized into two classes:
above and below the cutpoint. The two groups of patients
were comparable with respect to age, sex, grade, nodal
involvement and number of hepatic segments resected.
Maspin HSCORE was inversely correlated with gross neo-
plastic mass, estimated by the greatest tumor dimension
(P-value  = 0.0096) (see Figure 5A). The patients with
Maspin expression above the cutpoint had a mean tumor
mass of 4.26 ± 0.47 cm versus 6.83 ± 0.56 cm for those
patients below the cutpoint. In particular, it is of note that
the largest tumor mass was seen in the absence of Maspin
and Bax (mean value = 6.9 ± 1.02 cm); the Maspin expres-
sion (without a concomitant Bax expression) was associ-
ated with a smaller tumor mass (mean value = 5.36 ± 2.66
cm), while the simultaneous presence of Maspin and Bax
reduced further the mean tumor mass to 4.1 ± 1.4 cm. Stu-
dent's t-test revealed that only the simultaneous expres-
Immunoperoxidase staining of serial paraffin-embedded tissue sections of IHCCA of Maspin and Bax shows their expression in  cholangiocarcinoma cells (brown staining) Figure 1
Immunoperoxidase staining of serial paraffin-embedded tissue sections of IHCCA of Maspin and Bax shows 
their expression in cholangiocarcinoma cells (brown staining). Panels A and B refer to a 79-year-old female, Maspin 
HSCORE = 111 and Bax HSCORE = 95; panels C and D refer to a 71-year-old male, Maspin HSCORE = 70 and Bax HSCORE 
= 47.BMC Cancer 2006, 6:255 http://www.biomedcentral.com/1471-2407/6/255
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sion of Maspin and Bax was associated with a significant
(P-value = 0.015) reduction in tumor mass, while the sole
presence of Maspin was not associated with any signifi-
cant reduction (P-value = 0.250). This significance of the
relation between concomitant Maspin and Bax expression
with tumor mass reduction could be explained by
enhanced tumor cell apoptosis as shown by the occur-
rence of caspase-3 activation (see Figure 2A).
Similarly (see Figure 5B), the Maspin HSCORE was signif-
icantly related to the depth of tumor invasion (P-value =
0.043). The mean values of Maspin HSCORE for each pT-
stage were respectively: pT1 = 129.54 ± 25; pT2 = 68 ± 25;
pT3 = 48 ± 16.
It is widely accepted that necrosis is frequently associated
with the tumor mass. However, and in contrast to the rela-
tion of Maspin with tumor mass, we did not find any sig-
nificant relation to the extent of the necrosis (P-value =
0.550). As expected, in our cohort of patients the tumor
mass was significant related to the vascular invasion (P-
value  = 0.0018) (Figure 5C). We examined whether
Maspin over- expression affected vascular invasion in
IHCCA. Our results indicated an absence or presence of
vascular invasion when Maspin was above or below the
cutpoint, respectively (P-value = 0.027) (Figure 5D). The
Maspin HSCOREs were 98.3 ± 16 and 39 ± 18 in the
absence or in the presence of vascular invasion, respec-
tively. Moreover, the Maspin HSCORE was not related to
dysplasia of the intrahepatic bile ducts close to neoplastic
lesions, nor with the extent of lymphoid cell infiltration
(not shown).
We also wished to verify the potential role of Maspin as an
angiogenic inhibitor [30] by evaluating the relation
between Maspin expression and microvessel density. The
CD34-positive vessel count ranged from 7.5 to 54.4 ves-
sels·mm with a mean value of 34.8 ± 14.1 (median 38).
The standardized skewness and kurtosis values (-0.893
and -0.888, respectively) lay within the range expected for
data from a normal distribution.
The patients with Maspin HSCORE above the cutpoint
had a mean value of CD34- positive vessels of 36.5 ± 14.2
(median 41 vessels) and those below cutpoint had a mean
of 32.4 ± 14.3 (median 34 vessels) (P-value = 0.5170)
indicating a lack of statistical significance.
We finally evaluated the role of Maspin as a prognostic
factor [43,44]. The patients who underwent surgery dur-
ing the last year of enrolment and still alive were excluded
from the survival analysis. This choice was supported by
the fact that the follow-up period of these patients was
shorter than the median length of IHCCA overall survival
(18–30 months) [2,45]. The patients with a Maspin
HSCORE below the cutpoint had a shorter overall survival
(14 ± 10 months) than did patients with Maspin HSCORE
above the cutpoint (27 ± 18 months), whereas the log-
rank test showed no significant difference between the
two groups of patients (P-value = 0.162). Moreover, in the
evaluation of the relation between Maspin and/or Bax
Box-and-whisker plot for the presence or absence of Bax  expression versus Maspin HSCORE Figure 3
Box-and-whisker plot for the presence or absence of 
Bax expression versus Maspin HSCORE. The solid 
black circles represent the mean values. The solid black rep-
resent outlier patients with Maspin HSCORE outside the 
95% CI.
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Immunoperoxidase staining of apoptosis (cleaved caspase-3)  in IHCCA tissue sections (brown staining) Figure 2
Immunoperoxidase staining of apoptosis (cleaved 
caspase-3) in IHCCA tissue sections (brown staining). 
Immunohistochemical detection of cleaved caspase-3 in 
IHCCA specimens: Active caspase-3 staining displays a cyto-
plasmatic and/or nuclear pattern in neoplastic cells without 
morphological features of apoptosis.BMC Cancer 2006, 6:255 http://www.biomedcentral.com/1471-2407/6/255
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expression and survival there were no statistically signifi-
cant differences between the three groups (Logrank test P-
value  = 0.483): 37.3 ± 5.7 (Maspin+/Bax+), 27.2 ± 7.5
(Maspin+/Bax-), 21.7 ± 3.9 (Maspin-/Bax-) months,
respectively. It should be noted, however that the tumors
with an absence of both Maspin and Bax had the shortest
mean overall survival.
In our population, the following factors, when analyzed
with a univariate binary logistic regression, significantly
predicted the risk of death: Stage (P-value = 0.035) and
Maspin HSCORE (P-value = 0.025). The multivariable
logistic regression (Table 2) including the above-men-
tioned factors and those parameters with a P-value lower
than 0.2 (tumor greatest dimension, Glisson's capsule
invasion, invasion of resected margins) indicated that
only Maspin HSCORE, invasion of resected margins and
stage were independent prognostic factors in IHCCA.
Discussion
There is good experimental evidence that Maspin abol-
ishes tumor invasion [46], induces tumor re-differentia-
tion [47,48] and also enhances sensitivity of tumor cells
to apoptosis by inducing the apoptogenic Bax protein
[19,34,36,48]. Furthermore, suppression of Maspin
expression by siRNA desensitizes tumor cells to apoptosis
[35].
It has been reported that the apoptosis-sensitizing effect of
Maspin resulted predominantly from increased Bax
expression causing mitochondrial release of apoptogenic
factors such as cytochrome C and Smac/DIABLO [19].
We show here that Bax was expressed only when Maspin
reached a threshold value (cutpoint). We concluded that
Bax expression consequent to a Maspin level above the
cutpoint, shifted the relative concentration of anti- versus
pro-apoptotic members of the Bcl-2 family, thus acting as
a positive modulator of the death program. In our IHCCA
specimens, however, the concomitant occurrence of
Maspin and Bax did not correlate with a better prognosis.
In a recent paper [49], the over-expression of Bax in lung
cancer specimens suggested a pro-apoptotic cellular ten-
dency that did not correlate with a better prognosis. In
contrast, it has been shown [50] in metastatic breast ade-
nocarcinoma, that the expression of Bax protein is associ-
ated with increased overall survival and better response to
chemotherapy. However, a negative prognostic role of Bax
expression has been described in non-small-cell lung can-
cer [51]. Despite these contradictory results on the role of
Bax as a prognostic factor, its induction in Maspin-over-
expressing specimens seems to represent an important
mechanism by which Maspin delays tumor progression
and invasion.
The results presented here show for the first time that the
associated expression of Maspin and Bax, detected by
immunohistochemistry, significantly correlated with a
less aggressive phenotype. Thus, Maspin expression above
the cutpoint and the consequent Bax induction can help
to explain observations of opposite relations with neo-
plastic mass, depth of tumor invasion, and vascular inva-
sion. However, it should be noted that Maspin expression
was not related with the dysplasia of intrahepatic bile
ducts close to the neoplastic lesion, lymphoid cell infiltra-
tion, and the extent of necrosis of tumor mass.
We did not find any significant relation between micro-
vessel density and Maspin expression, although some-
what more CD34-positive vessels were observed in those
patients with Maspin above the cutpoint. This lack of rela-
tion is in contrast with studies showing that Maspin
inhibits angiogenesis [52] in vitro and in vivo in several
types of tumor. Due to its antiangiogenic effect Maspin
has been described as a tumor-suppressor protein. How-
ever, our results and a recent report [23] on the expression
of Maspin in non-muscle invasive urothelial bladder car-
cinoma suggest that in IHCCA and some other tumors
Maspin may exhibit its tumor-suppressor role by a mech-
anism unrelated with angiogenesis. Interestingly, it has
been shown that tumor neo-vessels become leaky after
Maspin treatment [31], whereas normal mature vessels are
not affected by Maspin treatment. In addition, it should
be noted that our CD34-antibody, a pan-endothelial
marker, used to highlight vasculature reveals mainly pre-
Optimal cutpoint determined using an approximation for  small samples Figure 4
Optimal cutpoint determined using an approxima-
tion for small samples. Optimal cutpoint determined using 
an approximation for small samples as described. The highest 
value, discriminant with respect to the occurrence of Bax 
expression, is 39.12
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Table 2: Multivariate logistic regression analysis.
Multivariate Logistic Regression
Prognostic factors Adverse Factor χ2 Df P-value
Tumor greatest dimension - 0.1335 1 0.7149
Maspin HSCORE - 3.8940 1 0.0485
Resected margins'invasion Yes 4.7674 1 0.0290
Glisson's capsule invasion Yes  2.0289 1 0.1543
Stage III 6.1012 2 0.0473
Relation between several prognostic factors and risk of death.
Maspin HSCORE versus tumor parameters Figure 5
Maspin HSCORE versus tumor parameters. Box-and-whisker plots of Maspin HSCORE above/below cutpoint and tumor 
dimension (A), of Maspin HSCORE versus depth of tumor invasion (B), and Maspin HSCORE versus vascular invasion (C). The 
open squares represent those outlier patients outside the 95% confidence interval. The black solid circles represent the mean 
values, while the line inside the box represents the median. (D) Bar-chart plot of patients with Maspin HSCORE above/below 
cutpoint versus vascular invasion.
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existing mature vessels and not tumor-induced neoves-
sels.
The caspase-3 activation was found related to the Bax
expression in the majority of IHCCA specimens. Interest-
ingly, in all tumor areas with activated caspase-3, a con-
comitant overexpression of Maspin and Bax was always
found. A subset of IHCCA had Bax overexpression with-
out a concomitant activated caspase-3 in tumor cells. A
similar finding has been reported in a tumorigenic epithe-
lial cell line [53]. An arrest of the intrinsic apoptotic path-
way could occur by different mechanisms such as the
impediment of the Bax pro-apoptotic conformational
change [36], overexpression of Bax-inhibitor [54], or the
prevention of the caspase cascade attributed to overex-
pression of heat shock proteins (mainly HSP27) [55].
The univariate logistic regression analysis has shown that
the factors significantly involved in the risk of death in
IHCCA are: staging and Maspin HSCORE. As shown in
Table 2, the multivariate logistic analysis indicated that
stage, Maspin HSCORE and resected margins' invasion are
independent factors for the risk of death. Univariate and
multivariate logistic analyses suggest a clear-cut relation
between the increased Maspin HSCORE and probability
to survive. Our results suggest that a routine assessment of
Maspin expression by immunostaining in IHCCA might
help detect those patients with a higher risk of death. They
are also consistent with the hypothesis, recently described
for other types of tumor [43,44,56,57], that reduced/
absent Maspin expression may predispose to an increased
risk of death. The non-parametric estimates of survival for
Maspin HSCORE cutpoint indicate that the mean survival
for those patients with HSCORE above the cutpoint was
related with longer overall survival although the logrank
test showed no significant difference in survival between
the patients.
The prognostic relevance of Maspin expression is a matter
of debate. For instance, some authors have described
Maspin expression as a prognostic marker for several
tumors [25,34,44,56-60]. In contrast, other authors feel
that Maspin expression [23,61] or overexpression [62] is
not a promising prognostic marker.
We also examined Maspin expression on the available
liver needle biopsies. Our results (not shown) suggest that
immunohistochemical negativity for Maspin clearly indi-
cates a neoplasm with a clinically aggressive course. On
the other hand, the immunopositivity is less informative
since we cannot exclude the presence of Maspin- negative
areas with a lesser degree of differentiation and with
aggressive potential.
Our study has the limitation of a low number of patients
that is too small to draw valid conclusions or conduct fur-
ther statistical analysis. The probability of correctly reject-
ing the null hypothesis (Power of test [63]) did not reach
the required amount of power. However, our cohort rep-
resents a large single institution series given the rarity of
this tumor.
A multicentric and randomized trial will be required to
validate our results performed in this explorative retro-
spective study. If confirmed in a large independent trial,
the expression of Maspin should help to discriminate
IHCCA patients with a better prognosis. Moreover, pre-
operative information retrieved from liver needle biopsies
could provide a basis for enroling those patients with a
likely unfavorable course for intensive pre-operative man-
agement. Finally, it should help devise novel strategies for
inducing Maspin expression in IHCCA tumor cells. This
procedure could restore tumor cell sensitivity towards a
broad range of apoptosis-inducing therapeutic interven-
tions designed to delay tumor progression.
Conclusion
Maspin expression is negatively associated with IHCCA
progression when Bax is expressed. The combined expres-
sion of Maspin and Bax may influence the susceptibility of
tumor cholangiocytes to apoptosis (as observed by
increased caspase-3 expression) and therefore may be
involved in delaying IHCCA progression. Procedures
designed to induce Maspin expression in IHCCA could
restore tumor cell sensitivity towards a broad range of
apoptosis-inducing therapeutic interventions and delay
tumor progression.
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